Semaglutide vs. Tirzepatide: Comparing GLP-1 Weight Loss Options

The two most prescribed weight loss peptides — semaglutide and tirzepatide — both belong to the incretin-based medication class but work through different mechanisms. For patients trying to decide between them, the differences in efficacy, side effects, cost, and availability matter. This guide provides a direct comparison.

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which reduces appetite by signaling satiety centers in the brain, slows gastric emptying so food stays in the stomach longer, improves insulin sensitivity, and reduces glucagon secretion. Brand names include Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral, diabetes).

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual mechanism provides all the GLP-1 benefits listed above plus additional GIP-mediated effects on insulin secretion, fat metabolism, and appetite regulation. Brand names include Mounjaro (diabetes) and Zepbound (weight loss).

Efficacy Comparison

Head-to-head data comes from the SURPASS-2 trial (diabetes patients), which compared tirzepatide directly against semaglutide. In this trial, tirzepatide at all doses produced greater HbA1c reduction than semaglutide 1mg, and tirzepatide at higher doses produced greater weight loss. In their respective weight loss trials — STEP (semaglutide) and SURMOUNT (tirzepatide) — the average weight loss results were approximately 14.9 percent with semaglutide 2.4mg over 68 weeks (STEP 1) and approximately 22.5 percent with tirzepatide 15mg over 72 weeks (SURMOUNT-1). These are averages — individual results vary significantly. Some patients respond better to one medication than the other.

Side Effect Comparison

Both medications share a similar gastrointestinal side effect profile, which is their most common category of adverse effects. Nausea affects roughly 40-45 percent of patients on either medication during dose escalation. Vomiting, diarrhea, and constipation occur at similar rates. The SURPASS-2 head-to-head data showed comparable GI side effect rates between the two medications. In both cases, side effects are typically worst during dose titration and improve as the body adjusts. Slow, gradual dose escalation is the primary strategy for managing GI side effects with either medication.

Cost Comparison

Brand-name pricing is similar: Wegovy (semaglutide) and Zepbound (tirzepatide) both carry list prices of roughly $1,000 to $1,600 per month without insurance. Insurance coverage varies — many plans now cover one or both medications for qualifying patients (typically BMI 30+ or BMI 27+ with comorbidities). Compounded versions of both medications are available from licensed 503B pharmacies at $200 to $500 per month. Compounded tirzepatide may be slightly more expensive than compounded semaglutide at some pharmacies due to the more complex molecule. One important regulatory difference: tirzepatide remains on the FDA drug shortage list as of April 2026, giving compounding pharmacies clearer legal authority to produce it. Semaglutide was removed from the shortage list in early 2025, and the FDA has since tightened enforcement against compounded semaglutide — though it remains available through 503A pharmacies under patient-specific prescriptions. For complete pricing information, see our peptide therapy cost guide.

Which One Is Right for You?

Neither medication is universally "better." Consider tirzepatide if you need maximum weight loss and your physician recommends it, if you have tried semaglutide without adequate results, or if you have Type 2 diabetes with significant insulin resistance (the dual mechanism may provide better glycemic control). Consider semaglutide if you want more prescribing options (longer track record, more physicians experienced with it), if cost is a factor (slightly more widely available as compounded), if you prefer the oral option (Rybelsus is available for diabetes, though weight loss doses are injectable), or if your insurance specifically covers Wegovy but not Zepbound.

The most important step is consulting a qualified physician who can evaluate your individual health profile and recommend the most appropriate medication. Browse our semaglutide clinics directory for providers who prescribe both medications.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any treatment. Last reviewed: April 2026.